GP IIb/IIIa inhibitors in coronary artery disease management: What the latest trials tell us

D. P. Chew, D. J. Moliterno

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.

Original languageEnglish
Pages (from-to)1017-1023
Number of pages7
JournalCleveland Clinic Journal of Medicine
Issue number12
Publication statusPublished - 1 Jan 2001
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this